SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The company effected a 1-for-10 reverse stock split of Class A common stock via a Certificate of Amendment to the Certificate of Incorporation filed with Delaware on June 8, 2026, with trading on a split-adjusted basis commencing June 9, 2026.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final results of the Company's 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing presents voting tallies for two proposals: election of three Class I directors (Robert A. Lenz, Rebecca Luse, and Ran Nussbaum) and ratification of BDO USA, P.C. as independent auditor. All proposals passed with substantial majorities. Shareholder vote results are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →This Item 8.01 disclosure concerns a prospectus supplement amendment registering additional resale shares (39,843 shares) issued as consideration in the Company's acquisition of Brex Inc., which closed April 7, 2026. While the underlying M&A transaction is material, this specific filing is a routine registration statement amendment for resale of acquisition consideration shares—a procedural capital markets disclosure rather than a new material event. The acquisition itself would have been disclosed in a prior 8-K; this filing merely updates the resale registration mechanics.
View raw filing on EDGAR →Stifel Financial Corp. held its Annual Meeting of Shareholders on June 9, 2026, with shareholders voting on five proposals: election of twelve directors, advisory vote on named executive officer compensation, amendment to the Certificate of Incorporation to increase authorized shares from 197 million to 294 million total shares and from 194 million to 291 million common shares, amendment to the 2001 Incentive Stock Plan to increase share capacity by 9,000,000 shares, and ratification of KPMG LLP as independent auditor. All proposals were approved with detailed voting tallies disclosed.
View raw filing on EDGAR →Getaround completed the sale of its entire European business to GoMore ApS for approximately €31.5 million plus contingent consideration, effective April 30, 2026, as part of the Company's orderly wind-down strategy. The transaction included a significant debt restructuring with Mudrick Capital involving cancellation of approximately $121.7 million in senior secured indebtedness and issuance of a super priority secured promissory note.
View raw filing on EDGAR →On June 5, 2026, the Board determined that voluntary dissolution of the Company under Delaware General Corporation Law Section 275 et seq. is in the best interests of the Company and its residual claimants, requiring stockholder approval.
View raw filing on EDGAR →Aaron M. Kale was appointed as Chief Accounting Officer (principal accounting officer) effective June 8, 2026, following Suzanne M. Thuerk's resignation notice on June 4, 2026. While the disclosure includes both a departure and an appointment, the principal disclosed action centers on the appointment of Kale to the principal accounting officer role, a material executive position. The filing emphasizes Kale's qualifications and transition support, making the appointment the salient event.
View raw filing on EDGAR →Sempra closed a $1 billion public offering of floating-rate notes due 2028, netting approximately $998.5 million in proceeds. While this is a material capital-raising event affecting the company's financial position and liquidity, it does not fit cleanly into the standard 8-K taxonomy—it is neither a debt covenant breach, a dilutive equity issuance, nor an M&A transaction. The disclosure is material to investors as it represents a significant debt financing, but the absence of a more specific category warrants classification as other_material.
View raw filing on EDGAR →Lakeland Industries disclosed financial results for the first quarter ended April 30, 2026, via press release filed under Item 2.02, with supplemental slides for an earnings call scheduled for June 9, 2026.
View raw filing on EDGAR →Wolfspeed disclosed unaudited pro forma financial information reflecting the effects of its prepackaged Chapter 11 plan of reorganization (effective September 29, 2025), fresh start accounting under ASC 852, and receipt of regulatory approvals (January 29, 2026). While the bankruptcy filing itself would have been disclosed as a bankruptcy_filing event, this Item 8.01 disclosure is a post-emergence update providing pro forma financials to investors. This is material to investors assessing the company's financial position post-reorganization, but does not fit neatly into the more specific event categories (the bankruptcy occurred in 2025; this is a 2026 informational update). The disclosure is substantive and would affect a reasonable investor's understanding of the company's financial condition.
View raw filing on EDGAR →Hubbell Inc. completed its acquisition of NSI Industries, a provider of electrical fittings, connectors, components, and wire management products, on June 9, 2026. The completion of this material acquisition was disclosed via press release and represents a significant strategic expansion of the registrant's business scope.
View raw filing on EDGAR →Shattuck Labs announced Phase 1 clinical trial data for its lead DR3 blocking antibody SL-325, demonstrating favorable safety, tolerability, and pharmacokinetic results with low immunogenicity (3.7% ADA rate). The company outlined material clinical milestones including initiation of Phase 2b trial (RECEPTIVE-CD1) in Q3 2026 and an IND filing for SL-846 in H1 2027, while simultaneously raising approximately $54.9 million in gross proceeds through warrant exercises (96% of outstanding warrants from August 2025 private placement).
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Interactive Strength's June 8, 2026 annual meeting of stockholders. The filing presents voting outcomes for eight proposals, including director elections (Trent A. Ward and Kirsten Bartok Touw), ratification of Deloitte & Touche LLP as auditor, approval of dilutive issuances related to Wattbike and Ergatta acquisitions, stock plan amendments, reverse stock split authority, and advisory votes on executive compensation. The disclosure of shareholder vote results is material as it confirms stockholder approval of significant corporate actions including M&A-related equity issuances and governance matters.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 5, 2026 Annual Meeting of Stockholders, covering three proposals: election of directors, ratification of the independent auditor (KPMG LLP), and an advisory vote on named executive officer compensation. The filing presents final vote tallies for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Adaptive Biotechnologies' June 5, 2026 annual meeting, covering three proposals: election of two Class I directors (Hershberg and Owen), advisory vote on 2025 named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed voting tallies and percentages match the shareholder_vote_results taxonomy precisely, and the results are material to investors assessing board composition and governance.
View raw filing on EDGAR →Affiliated Managers Group entered into a Fourth Amended and Restated Credit Agreement on June 9, 2026, establishing a $1.25 billion senior unsecured multicurrency revolving credit facility maturing in 2031, with an option to increase commitments by up to $750 million. This refinancing and amendment of the existing credit facility constitutes a material definitive agreement affecting the Company's capital structure and financial flexibility.
View raw filing on EDGAR →Cheniere Partners closed a $1.75 billion private placement of senior notes on June 9, 2026, consisting of $1 billion 2036 Notes and $750 million 2056 Notes, pursuant to supplemental indentures. This material debt financing activity affects the company's capital structure and financial obligations.
View raw filing on EDGAR →Relay Therapeutics held its 2026 Annual Meeting of Stockholders, at which shareholders voted on and approved four proposals: election of class III directors Douglas S. Ingram and Claire Mazumdar, Ph.D.; a non-binding advisory vote on executive compensation; ratification of Ernst & Young LLP as independent auditor; and approval of an amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 450 million. All proposals passed with substantial majorities.
View raw filing on EDGAR →Cheniere Partners closed a $1.75 billion private placement of senior notes ($1 billion 2036 Notes and $750 million 2056 Notes) on June 9, 2026. While this is a debt issuance rather than a traditional M&A transaction, Item 1.01 covers "Entry into a Material Definitive Agreement," and the closing of a material debt offering constitutes a significant financing event that would materially affect a reasonable investor's assessment of the company's capital structure and financial obligations. The substantial principal amounts and long maturities (10 and 30 years) make this material.
View raw filing on EDGAR →Novanta entered into a Securities Purchase Agreement for a private placement of approximately 2,142,857 common shares at $140.00 per share for approximately $300 million, representing approximately 6% dilution to existing shareholders. The unregistered equity sale under Section 4(a)(2) was announced with forward-looking statements regarding registration of the shares.
View raw filing on EDGAR →Talos Energy held its Annual Meeting of stockholders and disclosed voting results on four proposals: election of six director nominees, advisory approval of named executive officer compensation, approval of the Second Amended and Restated 2021 Long Term Incentive Plan (increasing shares by 4.5 million and extending the plan term), and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →This disclosure reports the final receipt of $4.0 million from AstraZeneca as the second and final holdback under the Share Purchase Agreement for the sale of Kyntra Bio's China operations, which closed on August 29, 2025 for approximately $220 million in total consideration. The completion of all post-closing payments under a material acquisition/disposition agreement is a significant event affecting the company's cash position and the finalization of a major transaction.
View raw filing on EDGAR →Nuburu entered into a binding Head of Terms with SunCubes S.r.l. on June 4, 2026, committing to a €1,000,000 investment for a minority stake in SunCubes and establishing an industrial cooperation framework for developing laser-arm systems. This constitutes a material acquisition activity under Item 1.01, involving capital commitment, equity acquisition, and strategic technology partnership that would materially affect investor assessment of the company's growth strategy and capital allocation.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Axsome's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting outcomes for three proposals: election of two Class II directors (Mark Saad and Susan Mahony, Ph.D., MBA), ratification of Deloitte & Touche LLP as independent auditor, and non-binding advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →The Compensation Committee approved adoption of a new Executive Severance and Change in Control Plan effective June 5, 2026, which establishes severance and change-in-control benefits for named executive officers and other key employees. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The plan specifies tiered severance payments, equity acceleration, and COBRA benefits triggered by qualifying termination events, making it material to investor assessment of executive compensation obligations.
View raw filing on EDGAR →MSD Investment Corp. priced a $300 million offering of 6.375% notes due 2029 in a private placement to qualified institutional buyers under Rule 144A and Regulation S. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, the event does not fit cleanly into the provided taxonomy. The "dilutive_issuance" category is defined as unregistered equity sales (private placements, PIPEs, convertible notes, ATM offerings), but this disclosure concerns debt notes, not equity. This is more accurately a debt financing event, which falls under "other_material" as it lacks a dedicated 8-K classification but materially affects the registrant's financial position.
View raw filing on EDGAR →Enliven Therapeutics held its Annual Meeting of Stockholders on June 9, 2026, with voting results on five proposals: election of two Class III directors (Richard Fair and Lori Kunkel), ratification of Deloitte & Touche LLP as independent auditor, approval to increase authorized common shares from 100 million to 200 million, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency.
View raw filing on EDGAR →Brian C. Thomas, Ph.D. resigned from his position as a member of the Board of Directors effective June 9, 2026, with the Company confirming the resignation was not due to disagreement.
View raw filing on EDGAR →Shareholders voted at the June 9, 2026 annual meeting to elect Juergen Eckhardt and Eric Bjerkholt as Class II Directors and to ratify PricewaterhouseCoopers LLP as the Company's independent auditor, with detailed voting tallies disclosed.
View raw filing on EDGAR →Darlene Deptula-Hicks was appointed as a Class III director and Chair of the Audit Committee following the 2026 Annual Meeting of Shareholders held on June 9, 2026. The appointment was disclosed via press release and includes compensatory arrangements consisting of stock options and annual fees.
View raw filing on EDGAR →Shareholders voted at the 2026 Annual Meeting on June 9, 2026, approving three proposals: election of director Todd C. Brady, M.D., Ph.D. (23,026,101 votes for); ratification of BDO USA, P.C. as independent auditor (43,693,772 votes for); and advisory approval of named executive officer compensation (19,477,504 votes for). Vote counts, abstentions, and broker non-votes were disclosed for each proposal.
View raw filing on EDGAR →Inflection Point Acquisition Corp. III entered into Amendment No. 2 to its Business Combination Agreement with Air Water Ventures Holdings Limited, materially reducing aggregate base consideration from $300M to $200M, restructuring earnout triggering events, and reducing maximum earnout shares from 30M to 20M.
View raw filing on EDGAR →The filing discloses an unregistered sale of 2,701,420 shares of common stock by certain stockholders acquired in connection with Ondas Inc.'s acquisition of Omnisys Ltd. The shares are being registered for resale via a prospectus supplement to an S-3ASR registration statement. This represents a dilutive equity issuance material to investors assessing ownership and capital structure, particularly given the acquisition context and the substantial share count involved.
View raw filing on EDGAR →The filing discloses entry into a Business Combination Agreement dated May 25, 2026, between Axiom Intelligence Acquisition Corp 1 (SPAC) and Terra Quantum AG, representing a material acquisition/merger transaction. The disclosure details the parties, agreement structure, and contemplated shareholder vote, which are hallmarks of M&A activity under Item 1.01 or 2.01. This is a transformative event for the SPAC and would materially affect investor assessment of the registrant.
View raw filing on EDGAR →The disclosure announces a mandatory separation of the Company's units into separately traded Class A Ordinary Shares (ticker "APUR") and Rights (ticker "APURR") effective June 10, 2026. While this is a structural capital markets event affecting how the Company's securities trade, it does not fit neatly into the more specific event categories (not an M&A activity, not a dilutive issuance, not a delisting). The event is material to investors as it changes the trading mechanics and liquidity profile of the Company's securities, warranting disclosure under Item 8.01 as an "Other Event."
View raw filing on EDGAR →This Item 8.01 disclosure centers on a Forward Purchase Agreement entered into on June 1, 2026, in connection with Live Oak Acquisition Corp. V's proposed initial business combination with Teamshares Inc. The filing discloses the trust account redemption price ($10.55 per share as of June 8, 2026) and references the underlying Merger Agreement dated November 14, 2025 (as amended). While the Item 8.01 framing emphasizes the trust disclosure requirement, the substantive event is the material acquisition/business combination activity—the forward purchase transaction is a financing mechanism directly tied to the proposed merger. This is a core M&A event material to investors assessing the registrant's strategic direction and capital structure.
View raw filing on EDGAR →Jasper Therapeutics received written notice from Nasdaq on June 3, 2026, that its voting common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has been granted an initial 180-day compliance period (until November 30, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met. This is a classic delisting risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public trading status.
View raw filing on EDGAR →This Item 5.07 discloses the results of an annual stockholder meeting covering three proposals: election of three directors (Charles Biederman, Patrick J. Callan Jr., and Jeffrey A. Gould), a non-binding advisory vote on executive compensation for 2025, and ratification of Ernst & Young LLP as independent auditors for 2026. The detailed voting tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure required by Item 5.07, making this a textbook shareholder vote results event.
View raw filing on EDGAR →Rain Enhancement Technologies issued 10,283,984 shares of Class A Common Stock unregistered, including a $4,000,000 debt-to-equity conversion from RHY Management LLC (affiliated with Chairman Harry You) and grants to officers, directors, advisors, and consultants, relying on Section 4(a)(2) and Regulation D exemptions. This represents material dilution to existing shareholders and a significant capital structure change.
View raw filing on EDGAR →Rain Enhancement Technologies issued 50,000 shares of Class A Common Stock to interim CFO Oanh Truong as compensation for services pursuant to the 2024 Equity Incentive Plan.
View raw filing on EDGAR →Rain Enhancement Technologies issued 490,000 shares of Class A Common Stock as deferred compensation to six directors (Dickerson, Steele, Reardon, Peperzak, Riley, Sylvester), a Senior Technology Advisor (Morris), and an independent contractor (Monroe) pursuant to the 2024 Equity Incentive Plan and previously-disclosed Director Agreements.
View raw filing on EDGAR →The filing discloses a mandatory unit separation effective June 11, 2026, whereby the Company's units will cease trading and the underlying ordinary shares and rights will commence separate trading on Nasdaq under new ticker symbols "BREZ" and "BREZR." This is a material corporate action affecting the trading structure and liquidity of the Company's securities, but does not fit neatly into the more specific event categories (it is not M&A, an executive change, a restatement, or other enumerated events). The mandatory nature and automatic separation make this a material structural change warranting disclosure.
View raw filing on EDGAR →Mr. Matan Fattal resigned as a director and member of multiple committees effective June 5, 2026. While the resignation itself was not disputed, the departure triggered material consequences: the Company lost compliance with Nasdaq Listing Rule 5605(c)(2)(A) (minimum three-member audit committee) and 5605(b) (majority independent board requirement), creating delisting risk that a reasonable investor would find material to their investment decision.
View raw filing on EDGAR →MoonLake Immunotherapeutics held an Annual Meeting of shareholders at which four proposals were voted on and approved: election of Class I director Spike Loy, ratification of Baker Tilly US, LLP as independent auditor, advisory vote on executive compensation, and approval of an amendment and restatement of the 2022 Equity Incentive Plan increasing available shares by 5,000,000 and extending the plan term to 2036.
View raw filing on EDGAR →The Company received notification from Nasdaq that it failed to meet the Minimum Public Holders Rule (Listing Rule 5550(a)(3)) and has been granted an extension through October 3, 2026 to regain compliance. This is a classic delisting risk disclosure under Item 3.01, indicating the Company is at risk of losing its Nasdaq listing if it cannot cure the deficiency within the extension period.
View raw filing on EDGAR →Aditxt entered into a Note Purchase Agreement on June 3, 2026, issuing senior secured convertible notes with an aggregate principal amount of approximately $725,000 in cash proceeds plus consolidation of existing notes totaling $4.4+ million to accredited investors under Section 4(a)(2) and Regulation D Rule 506(b). The unregistered private placement of convertible securities is material to investors due to ownership dilution and capital structure effects.
View raw filing on EDGAR →Big Digital Energy amended and terminated its Rights Agreement (poison pill) effective June 8, 2026, with the Board determining that an active Rights Agreement is no longer needed. This material corporate governance action, disclosed via press release and charter amendment, signals a strategic shift in the Company's takeover defenses and capital structure posture.
View raw filing on EDGAR →The Company's previously announced AI/HPC colocation services agreement with BE Global Development Limited (executed August 9, 2024) has failed to advance to deployment, with key objectives unmet and no revenue received or expected, rendering the project inactive. This material business development failure affects investor assessment of the Company's growth prospects and pipeline.
View raw filing on EDGAR →BRC Group Holdings disclosed unregistered sales of equity securities under Item 3.02 that exceeded 5% of outstanding shares. The Company issued 2,060,683 shares of Common Stock in two private exchanges (May 14 and June 4, 2026) in exchange for cancellation of senior notes, representing approximately 5.1% of the 40.2 million shares outstanding as of June 4, 2026. This is a classic dilutive issuance under Section 3(a)(9) of the Securities Act, material to investors assessing ownership dilution and the Company's capital structure.
View raw filing on EDGAR →Live Oak Acquisition Corp. V has entered into Non-Redemption Agreements with shareholders and its Sponsor in connection with its proposed business combination with Teamshares Inc., a transaction previously disclosed under a Merger Agreement dated November 14, 2025. The Non-Redemption Agreements are material ancillary agreements to the business combination, designed to reduce public share redemptions at the June 16, 2026 shareholder meeting. This disclosure under Item 1.01 reflects a definitive agreement directly supporting the consummation of the proposed business combination.
View raw filing on EDGAR →